Poseida Therapeutics, Inc. (NASDAQ:PSTX) Expected to Earn FY2023 Earnings of ($1.62) Per Share

Poseida Therapeutics, Inc. (NASDAQ:PSTX – Get Rating) – Analysts at Cantor Fitzgerald issued their FY2023 earnings per share (EPS) estimates for shares of Poseida Therapeutics in a research note issued on Monday, March 13th. Cantor Fitzgerald analyst J. Kim expects that the company will post earnings per share of ($1.62) for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $24.00 target price on the stock. The consensus estimate for Poseida Therapeutics’ current full-year earnings is ($1.50) per share.

Separately, HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Poseida Therapeutics in a research note on Friday, March 10th.

Poseida Therapeutics Price Performance

NASDAQ:PSTX opened at $4.19 on Thursday. Poseida Therapeutics has a 1 year low of $1.82 and a 1 year high of $8.82. The company has a debt-to-equity ratio of 0.31, a current ratio of 5.54 and a quick ratio of 5.54. The firm has a market capitalization of $362.56 million, a price-to-earnings ratio of -3.84 and a beta of 0.37. The business has a 50 day simple moving average of $6.55 and a 200-day simple moving average of $5.10.

Institutional Investors Weigh In On Poseida Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. EcoR1 Capital LLC bought a new stake in Poseida Therapeutics during the 3rd quarter valued at $9,355,000. Silverarc Capital Management LLC raised its position in Poseida Therapeutics by 571.1% during the 3rd quarter. Silverarc Capital Management LLC now owns 2,554,277 shares of the company’s stock valued at $9,017,000 after purchasing an additional 2,173,671 shares in the last quarter. Cormorant Asset Management LP bought a new stake in Poseida Therapeutics during the 3rd quarter valued at $6,531,000. Millennium Management LLC raised its position in Poseida Therapeutics by 984.9% during the 4th quarter. Millennium Management LLC now owns 1,646,897 shares of the company’s stock valued at $8,729,000 after purchasing an additional 1,495,099 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in Poseida Therapeutics by 79.9% during the 3rd quarter. Vanguard Group Inc. now owns 2,384,866 shares of the company’s stock valued at $8,419,000 after purchasing an additional 1,059,216 shares in the last quarter. 46.67% of the stock is owned by institutional investors.

Poseida Therapeutics Company Profile

(Get Rating)

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC).